Study #2016-1130
A PHASE I STUDY OF DS-3201B IN SUBJECTS WITH ACUTE MYELOGENOUS LEUKEMIA (AML);OR ACUTE LYMPHOCYTIC LEUKEMIA (ALL)
Study Status
Open
Treatment Agent
DS-3201
Principal Investigator
Naval Daver
Description
There are 2 parts in this study: Part 1 (dose escalation) and Part 2 (dose expansion). The goal of Part 1 of this clinical research study is to find the highest tolerable dose of DS-3201b that can be given to patients with acute myelogenous leukemia (AML) or acute lymphocytic leukemia (ALL). The goal of Part 2 of this study is to learn if the dose of DS-3201b found in Part 1 can help to control AML or ALL. The safety of DS-3201b will be studied in both parts.
General Information
Disease Group: Malignant neoplasms stated as primary lymphoid haematopoietic
Treatment Agent: DS-3201
Treatment Location: Both at MD Anderson & Other Sites
Sponsor: Daiichi Sankyo, Inc
Study Status
IRB Review and Approval Date: 03/29/2017
Recruitment Status: Open
Projected Accrual: 61
Resources and Links
Information and next steps
Disease:
Malignant neoplasms stated as primary lymphoid haematopoietic
Study phase:
Phase I
Physician name:
Naval Daver
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789